ストックスクリーナーアプリを入手
95.96
1.95%
1.99
Revvity Inc (RVTY) 最新ニュース
Can Revvity Expand Diagnostics Across the S&P 500 Index? - Kalkine Media
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance - simplywall.st
Revvity stock (US76155R1086): steady diagnostics player after latest quarterly update - AD HOC NEWS
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move - AD HOC NEWS
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): T. Rowe Price reports a 9% stake - AD HOC NEWS
FDA OKs Revvity’s Total Testosterone Assay - Medical Product Outsourcing
T. Rowe Price (RVTY) discloses 10.1M-share, 9.0% stake in Revvity - Stock Titan
(RVTY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS - AD HOC NEWS
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay - The Globe and Mail
BofA Securities Maintains Revvity(RVTY.US) With Hold Rating - Moomoo
Is Revvity stock underperforming the S&P 500? - MSN
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says U - GuruFocus
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says Undervalued - GuruFocus
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat - AD HOC NEWS
FDA Clears Revvity Total Testosterone Assay for Automated Testing - Clinical Lab Products
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution - Yahoo Finance
Revvity (RVTY) grows Q1 2026 sales to $711M while margins tighten - Stock Titan
Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains - AD HOC NEWS
RVTY Technical Analysis | Trend, Signals & Chart Patterns | REVVITY INC (NYSE:RVTY) - ChartMill
Revvity (NYSE:RVTY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity (RVTY) director Alexis Michas receives stock awards and reports indirect holdings - Stock Titan
REVVITY (RVTY) director granted new restricted stock unit awards - Stock Titan
Revvity (RVTY) director Michael Klobuchar receives new restricted stock unit grants - Stock Titan
Revvity (RVTY) director Frank Witney granted restricted stock unit awards - Stock Titan
Director Samuel R. Chapin receives stock awards at REVVITY (RVTY) with RSUs vesting in 2027 - Stock Titan
Revvity (RVTY) director Michel Vounatsos receives new restricted stock units - Stock Titan
Revvity (RVTY) director Michelle McMurry-Heath granted new RSU awards - Stock Titan
Equity grants add 2,280 shares to Revvity (RVTY) director’s stake - Stock Titan
Revvity (RVTY) Q1 2026 Earnings Transcript - AOL.com
Revvity stock (US76155R1086): Q1 beat and analyst upgrade spark gains - AD HOC NEWS
Mitsubishi UFJ Asset Management Co. Ltd. Trims Stake in Revvity Inc. $RVTY - MarketBeat
Revvity (RVTY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Revvity earnings: What to look for from RVTY - MSN
Revvity outlines 3%-4% 2026 organic growth and $5.20-$5.30 EPS while planning China immunodiagnostics divestiture - MSN
Revvity Inc. stock (US76155R1086): Barclays lifts price target as Q1 beats estimates - AD HOC NEWS
Revvity, Inc. (NYSE:RVTY) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
Revvity, Inc. (NYSE:RVTY) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Revvity declares $0.07 dividend - MSN
RVTY Maintained by Barclays -- Price Target Raised to $105 - GuruFocus
Stifel Maintains Revvity(RVTY.US) With Hold Rating, Cuts Target Price to $100 - Moomoo
Revvity Is Maintained at Equal-Weight by Barclays - Moomoo
Revvity (RVTY) Net Margin Deterioration Tests Bullish Recovery Narratives Ahead Of Q1 2026 - Sahm
Is Revvity’s (RVTY) China Exit and EPS Reset Quietly Rewriting Its Portfolio Strategy? - Yahoo Finance
Goldman Sachs Maintains Revvity(RVTY.US) With Hold Rating, Cuts Target Price to $100 - Moomoo
RVTY Q1 2026 deep dive: Portfolio pruning and AI investments shape outlook - MSN
Barclays Maintains Revvity(RVTY.US) With Hold Rating, Raises Target Price to $105 - Moomoo
Revvity Q1 Adjusted Earnings, Revenue Rise - Moomoo
Stifel cuts Revvity stock price target on softer valuation By Investing.com - Investing.com South Africa
MSN Money - MSN
Research Alert: CFRA Maintains Buy Rating On Shares Of Revvity - Moomoo
Stifel cuts Revvity stock price target on softer valuation - Investing.com UK
Revvity, Inc. (NYSE:RVTY) Q1 2026 Earnings Call Transcript - Insider Monkey
1.19%
0.06%
大文字化:
|
ボリューム (24 時間):